DOVATO is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of DOVATO.
See trial results for a switch to DOVATO in appropriate virologically suppressed adults
GEMINI 1 & 2 Trials
See trial results and 96-week long-term data
Risks & Side Effects
Info about the possible risks and side effects, including drug-related adverse events and rates of discontinuation